ArticleGenes, chromosomes & cancer2025
Resurfacing Threats: Metastatic Ossifying Fibromyxoid Tumor Emerging After Almost Two Decades.
Article in Genes, chromosomes & cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Ossifying fibromyxoid tumor of the hand: a case report and review of surgical intervention.Journal of surgical case reports · 2026Article
- Resurfacing Threats: Metastatic Ossifying Fibromyxoid Tumor Emerging After Almost Two Decades.Genes, chromosomes & cancer · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOssifying fibromyxoid tumor (OFMT) is an extremely rare mesenchymal tumor of uncertain differentiation having a potential for local recurrences and metastasis. OFMT can be classified as typical, atypical, and malignant tumors based on nuclear grade, cellularity, and mitotic rate. However, predicting the biological behavior remains challenging. We report one of these challenging cases of OFMT with metastases after 19 years. The primary tumor did not show morphologic characteristics of malignancy. We performed targeted RNA sequencing, copy number variation (CNV) analysis on all lesions and additional DNA methylation profiling. PRESENTATION OF THE CASE: Herein we report the case of a 66-year-old Caucasian female patient diagnosed in 2004 with an OFMT on her back that was surgically removed. In August 2023, the patient presented with two new soft tissue lesions in the right lower thigh and left gluteal area. Biopsy has been performed on both lesions. Pathology reports demonstrated an OFMT with an EP400:PHF1 fusion. Both tumors were confirmed to represent the identical entity. Surgical removal of both tumors was performed with clear margins. The presence of late sequential metastases 19 years after initial resection of an OFMT, without any signs of malignancy after pathology review of the 2004 lesion was suggested. In December 2023, a potential fourth similar mass was detected with MRI and a full body PET-CT within the distal left semimembranosus muscle. A biopsy of this lesion has not been performed yet. It is currently being closely monitored through regular MRI examinations with contrast agents at intervals of 3 months.
conclusionThis case demonstrates the rare unpredictable potential of even typical OFMT to develop multiple soft tissue metastases after 19 years. Therefore, clinicians need to be aware of the metastatic potential of this tumor. Comprehensive and prolonged postoperative follow-up is necessary to track local recurrences and metastases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.